A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Tuesday, 11 October 2011
From information posted on the IPKat today it can be seen that the underlying dispute involves a patent and a supplementary protection certificate for levofloxacin hemihydrate, an active ingredient of a product sold under the trade mark TAVANIC.